1-methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazine | 870078-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazine
• 英文别名: 1-Methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)piperazine；1-methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yl)piperazine
• CAS: 870078-77-6；870079-22-4；870079-23-5
• 化学式: C₂₀H₂₅N₃
• 分子量: 307.439
• InChiKey: NIEJYUQKVDOOSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  19.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazine 在 platinum(IV) oxide 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 以62%的产率得到1-methyl-4-(7-piperidin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazine
  参考文献：
  名称：

  [EN] TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS
  [FR] TETRAHYDRONAPHTHYLPIPER- AZINES UTILISEES EN TANT QU'AGONISTES INVERSES, AGONISTES PARTIELS ET ANTAGONISTES DE 5-HT1B

  摘要：

  本发明涉及新型四氢萘哌嗪衍生物，即式(I)中R1、R2和R6如本文所定义，X为CH2或O，A为下图所示的式(G1、G2、G2a、G3、G4、G5或G6)的基团，D为式(D)的基团，其中Y、W和Z为C或N，R7如本文所定义，以及它们的盐和组合物，包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病中具有用途。

  公开号：

  WO2005113527A1
• 作为产物：
  描述：

  1-methyl-4-[7-(4,4,5.5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-piperazine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride sodium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 、 水 为溶剂， 反应 16.0h， 生成 1-methyl-4-(7-pyridin-4-yl-1,2,3,4-tetrahydro-naphthalen-1-yl)-piperazine
  参考文献：
  名称：

  [EN] TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS
  [FR] TETRAHYDRONAPHTHYLPIPER- AZINES UTILISEES EN TANT QU'AGONISTES INVERSES, AGONISTES PARTIELS ET ANTAGONISTES DE 5-HT1B

  摘要：

  本发明涉及新型四氢萘哌嗪衍生物，即式(I)中R1、R2和R6如本文所定义，X为CH2或O，A为下图所示的式(G1、G2、G2a、G3、G4、G5或G6)的基团，D为式(D)的基团，其中Y、W和Z为C或N，R7如本文所定义，以及它们的盐和组合物，包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病中具有用途。

  公开号：

  WO2005113527A1

文献信息

• [EN] Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)<br/>[FR] UREE-OCTAHYDROINDOLES SUBSTITUES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE CONCENTRANT LA MELANINE (MCH1R)
  申请人：BIOVITRUM AB

  公开号：WO2005051381A1

  公开（公告）日：2005-06-09

  The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).

  该发明涉及通式（I）的化合物，其中R0、R1、R2、R3、R4、R5、R6、R7、R8、R9、Ar和X如描述中所定义，或其药学上可接受的盐、水合物、几何异构体、消旋体、互变异构体、光学异构体、N-氧化物及其前药形式。这些化合物可用于治疗或预防与MCH1R受体相关的疾病，并用于调节食欲。该发明还涉及该用途以及包含通式（I）化合物的药物配方。
• Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists
  申请人：Brodney A. Michael

  公开号：US20050288304A1

  公开（公告）日：2005-12-29

  The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula I wherein R 1 , R 2 and R 6 are as defined herein, X is CH 2 or O, A is a group of the formula G 1 , G 2 , G 2a , G 3 , G 4 , G 5 or G 6 depicted below, and D is a group of the formula D, wherein Y, W and Z are C or N and wherein R 7 is as defined herein and their salts and compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT 1 ) receptors. Compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT 1 agonist or antagonist is indicated.

  本发明涉及新型四氢萘基哌嗪衍生物，其为式I的化合物 其中R1，R2和R6如本文所定义，X为CH2或O，A为下列式G1，G2，G2a，G3，G4，G5或G6的基团， D为式D的基团，其中Y，W和Z为C或N，R7如本文所定义，以及它们的盐和组合物，包括选择性拮抗剂、反向激动剂和部分激动剂5-HT1受体。本发明中的化合物可用于治疗或预防抑郁症、焦虑症、强迫症和其他需要5-HT1激动剂或拮抗剂的疾病。
• [EN] HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE HTR1D ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER
  申请人：INST CURIE

  公开号：WO2020183011A1

  公开（公告）日：2020-09-17

  The present invention deals with a 5 -hydroxytryptamine receptor 1D (5-HTR1D) inhibitor and with a combination of a 5-HTR1D inhibitor and at least one inhibitor of 5 -hydroxytryptamine receptor 1B (5-HTR1B) for use in the prevention and/or treatment of cancer in a subject in need thereof. According to the invention the cancer may be selected from the group comprising breast cancer, liver cancer, lung cancer, brain cancer, mesothelioma, head and neck squamous cell carcinoma, kidney cancer, gastric cancer and cervix cancer.
• [EN] TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS<br/>[FR] TETRAHYDRONAPHTHYLPIPER- AZINES UTILISEES EN TANT QU'AGONISTES INVERSES, AGONISTES PARTIELS ET ANTAGONISTES DE 5-HT1B
  申请人：PFIZER PROD INC

  公开号：WO2005113527A1

  公开（公告）日：2005-12-01

  The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G6) depicted below, and D is a group of the formula (D), wherein Y, W and Z are C or N and wherein R7 is as defined herein and their salts and compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors. Compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.

  本发明涉及新型四氢萘哌嗪衍生物，即式(I)中R1、R2和R6如本文所定义，X为CH2或O，A为下图所示的式(G1、G2、G2a、G3、G4、G5或G6)的基团，D为式(D)的基团，其中Y、W和Z为C或N，R7如本文所定义，以及它们的盐和组合物，包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病中具有用途。